对REV-ERBα选择性激动剂SR-29065 (34) 对自身免疫性疾病的结构-活性关系和生物研究
相关实验视频
Updated: Jul 12, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
144
Yuanjun He1, Di Zhu1, Kevin Greenman2
1The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
Journal of medicinal chemistry
|October 27, 2023
概括
研究人员开发了一种针对REV-ERBα的新型化合物,用于治疗自身免疫性疾病. 这种化合物在小鼠模型中降低了T助手17 (TH17) 细胞活性,显示出新疗法的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫性疾病影响着数百万人,特别是女性,是导致死亡的主要原因.
- 基因研究表明,T辅助17 (TH17) 细胞在自身免疫性疾病中起着至关重要的作用.
- 核受体REV-ERBα和β被确定为TH17细胞功能的抑制剂和潜在的治疗标.
研究的目的:
- 在一个新的REV-ERBα选择性支架上进行结构-活动关系 (SAR) 研究.
- 为了优化体的代谢稳定性,用于*in vivo*研究.
- 评估REV-ERBα连接体在多发性硬化症临床前模型中的治疗潜力.
主要方法:
- 在新的REV-ERBα选择性支架上进行了详细的SAR研究.
- 结合体的代谢稳定性得到增强.
- 在实验性自身免疫脑膜炎 (EAE) 的小鼠模型中测试了一种特定的配体 (化合物34).
主要成果:
- 一个新的REV-ERBα选择性支架被开发出来,具有优化的代谢稳定性.
- 化合物34在EAE小鼠模型中证明了*in vivo*目标参与.
- 34化合物的使用导致中枢神经系统 (CNS) 中T细胞的频率和数量减少.
结论:
- REV-ERBα选择性联体代表了对自身免疫性疾病的有前途的治疗策略.
- 向REV-ERBα可以调节TH17细胞的致病性.
- 进一步开发REV-ERBα调节剂可能为诸如多发性硬化症等疾病提供新的治疗方法.
更多相关视频
相关概念视频
Structure-Activity Relationships and Drug Design
735
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
735
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Drug-Receptor Interactions
5.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.3K
Dose-Response Relationship: Selectivity and Specificity
6.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.8K

